Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review Topic of the Week.

Chronic kidney disease (CKD) and cardiovascular disease (CVD) have a significant inter-relationship in patients with diabetes. Controlling blood pressure, dyslipidemia, and glucose levels is a common treatment approach to managing CVD risk in patients with CKD and diabetes; despite strict control, however, a high residual risk remains. This review focuses on patients who require pharmacotherapy, in whom new and existing cardiorenal therapies (renin-angiotensin-aldosterone system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and nonsteroidal mineralocorticoid receptor antagonists) with differing mechanisms of action and safety profiles can reduce cardiovascular risk beyond the outcomes achieved with blood pressure, dyslipidemia, or glycemic control alone. Several treatment guidelines have been updated recently to reflect new evidence. Studies of these cardiorenal agents used in combination are ongoing, and results are awaited with interest, with the hope that potential synergistic effects may lead to further improvements in cardiovascular outcomes.

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures Medical writing support was funded by Bayer, in accordance with the 2022 Good Publication Practice guidelines. Dr Morales has received consultant and speaker honoraria from Novo Nordisk, Lilly, Boehringer Ingelheim, Abbott, Amgen, Bayer, Zealand Pharma, and Sanofi. Dr Handelsman has received research grants and consultant and speaker honoraria from Amarin, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Corcept, Esperion, Ionis, Mankind Pharma, Merck, Merck-Pfizer, Novartis, Novo Nordisk, Regor Therapeutics, Sanofi, and Vertis.